Toggle light / dark theme

Elena Milova speaking in support of OncoSENS crowdfunding campaign

The MMTP has recorded this film in support of SENS Research and their quest to find solutions to ALT cancer.


To support OncoSENS project with a donation click the link:

https://www.lifespan.io/campaigns/sens-control-alt-delete-cancer/

Telomere shortening acts as a biological mechanism for limiting cellular life span. Most cancer cells bypass this failsafe by synthesizing new telomeres using the enzyme telomerase.

Several therapies targeting this well-described telomerase-based pathway are in the advanced stages of clinical development, but as with any cancer therapy there is the potential for development of resistance against telomerase-based strategies to defeat cancer. Studies using mice and human cancer cell lines have demonstrated that cancer can overcome the loss of telomerase by using a telomerase-independent mechanism called Alternative Lengthening of Telomeres (ALT).

Furthermore, tumor cells have also been observed to switch over to the ALT pathway as a result of telomerase-inhibiting treatment.

From 10 to 15% of all cancers are ALT-dependent — and incurable, because there are currently no ALT-targeted anti-cancer therapeutics.

OncoSENS is a high-throughput screening of a library of diverse drugs to find treatments for ‘ALT’ cancers, those which rely on Alternative Lengthening of Telomeres.

Read more